CONTEXT: Oncology news article on use of RWR in oncology. Nothing new in terms of data use, more confirmation of RWD in oncology research. However, an interesting perspective from the Continue Reading
IMPACT: Preliminary RWE on effectiveness of single dose of Pfizer vaccine; 1st dose of the Pfizer vaccine seen to curb infection rates by 50% within 14 days; data from 800,000 Continue Reading
Comments – Part of the growing trend for big pharma to secure bid data sources for their own use. A move in the right direction towards ‘regulatory grade’ RWE. READ Continue Reading
COMMENTS: Good story on use of RWE / RWR in oncology. READ TIME: 2 mins *1. “Sir Mick Peake, clinical director for the Centre for Cancer Outcomes within UCLH’s Cancer Continue Reading
IMPACT: The power of numbers…real-world data from 3.5 million vaccinated Israeli’s shows impact/ effectiveness of the Pfizer vaccine during early phase of roll out. READ TIME: 2 min *1. “Among Continue Reading
CONTEXT: Some people lost a small amount of weight whilst in a study….. Interesting thing here is the reporting of RWE data during a study lifetime, which has statistical penalties Continue Reading
CONTEXT: European initiative to explore “In-Silico” research. Not so much “Real World” as “Brave New World” utilising computer models to test safety and efficacy of medical devices. Hopefully this isn’t Continue Reading
CONTEXT: Real world research showing value in rare disease research where RCTs cannot generate the statistical power traditionally needed with so few available patients. New methods to interpret the RWD Continue Reading
COMMENTS: Filling the gap between pharmaceutical grade cannabinoid derivative production through RWE. FDA will need to tighten up it’s response to CBD products with legal cannabis production booming in the Continue Reading
Comments – Part of the EMA’s continued commitment to RWE in support of medicinal product utilisation. When you see regulators investing in infrastructure like this, you know they are serious Continue Reading
